Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections.
Latest Information Update: 20 Sep 2022
Price :
$35 *
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Otitis media; Pneumococcal infections; Respiratory tract infections
- Focus Pharmacodynamics
- Acronyms PREV-IX_B; PREV-IX_BOOST
- 01 Sep 2022 Results (n=261; Between April 10, 2013, and Sept 4, 2018) assessing the immunogenicity of novel pneumococcal conjugate vaccine (PCV) schedules from PREVIX_COMBO and PREVIX_BOOST randomised controlled trials, published in The Lancet Infectious Diseases.
- 23 Mar 2020 Status changed from active, no longer recruiting to completed.
- 17 Oct 2018 Status changed from recruiting to active, no longer recruiting.